A Ropivacaine-Eluting Poly(Lactide-Co-Caprolactone) Wound Dressing Provided Enhanced Analgesia in Partial-Thickness Porcine Injuries
- PMID: 38652817
- DOI: 10.1097/PRS.0000000000011485
A Ropivacaine-Eluting Poly(Lactide-Co-Caprolactone) Wound Dressing Provided Enhanced Analgesia in Partial-Thickness Porcine Injuries
Abstract
Background: Partial-thickness skin wounds are some of the most painful injuries because of large areas of exposed nerve endings. These injuries often require systemic opioid treatment to manage pain adequately. However, the Centers for Disease Control and Prevention reported nearly 17,000 prescription opioid-related deaths in the United States in 2021 alone, highlighting the ongoing need for nonopioid treatment strategies. The authors developed a novel single-application ropivacaine-eluting primary wound dressing that could provide sustained ropivacaine delivery to partial-thickness wounds and assessed its in vivo feasibility for prolonged nonopioid analgesia.
Methods: Sustained release of ropivacaine from a poly(lactide-co-caprolactone) matrix was first optimized in vitro using dissolution testing and a Box Behnken design of experiments. The optimized dressing was then tested against a clinical control silicone dressing in a porcine partial-thickness wound study to assess analgesic effect, pharmacokinetics, and wound healing.
Results: The ropivacaine-eluting dressing showed a moderate analgesic effect in vivo, where normalized single pinprick scores significantly improved pain over the testing period (4 to 168 hours) (control versus treatment: 232 ± 25% versus 145 ± 16%; P < 0.0003). Ropivacaine blood plasma levels peaked at 8 hours after treatment, with a maximum concentration of 246 ± 74 ng/mL. No significant differences in wound healing were found when compared with control.
Conclusion: The ropivacaine-loaded poly(lactide-co-caprolactone)-based wound dressing provided sustained delivery of ropivacaine to partial-thickness skin wounds and enhanced analgesic effect compared with a clinical standard control dressing.
Clinical relevance statement: This article describes the development and porcine testing of an analgesic wound dressing for management of acute pain in partial-thickness dermal wounds.
Copyright © 2024 by the American Society of Plastic Surgeons.
References
-
- Serebrakian AT, Pickrell BB, Varon DE, et al. Meta-analysis and systematic review of skin graft donor-site dressings with future guidelines. Plast Reconstr Surg Glob Open 2018;6:e1928.
-
- McDermott KW, Weiss AJ, Elixhauser A. Burn-Related Hospital Inpatient Stays and Emergency Department Visits, 2013. Agency for Healthcare Research and Quality; 2006.
-
- Singer DD, Thode HC, Sandoval S, Singer AJ. 465 Time trends and disparities in burn related ED visits 2000–2014: a national perspective. J Burn Care Res. 2018;39:S205–S205.
-
- Centers for Disease Control and Prevention. National Hospital Ambulatory Medical Care Survey: 2017 emergency department summary tables. US Department of Health and Human Services; 2020.
-
- Demirtas Y, Yagmur C, Soylemez F, Ozturk N, Demir A. Management of split-thickness skin graft donor site: a prospective clinical trial for comparison of five different dressing materials. Burns 2010;36:999–1005.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources